NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Aurinia Pharmaceuticals Inc. (AUPH) Stock Analysis

Aurinia Pharmaceuticals Inc. (AUPH) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

AUPH

$16.90

+$0.16 (+0.96%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare AUPH with… →

AUPH Key Statistics

As of Oct 21, 2026
Trading
Open
$16.73
Previous Close
$16.74
Day's Range
16.64–17.01
52-Week Range
11.48–19.25
Volume
783.13K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.61
Valuation
Market Cap
$2.25B
P/E Ratio
7.41
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
15.97
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
7.22
EPS (ttm)Profit attributable to each share over the last twelve months.
2.28
Financials (FY)
Revenue (FY)
$283.06M+20.38%
Net Income (FY)
$287.20M+4,893.08%
Profit marginThe share of revenue left as profit after all costs and taxes.
100.84%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
133.05M
1-Year Return
+42.74%
Dividend and dates
Earnings Date
November 9, 2026estimated
Avg Volume
959.40K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, AUPH closed at $16.90, +42.74% over 1 year.

Aurinia Pharmaceuticals Inc. (AUPH) has a market capitalization of $2.25B.

In fiscal 2025, AUPH reported revenue of $283.06M.

AUPH Stock Return by Calendar Year

Aurinia Pharmaceuticals Inc. (AUPH) 10-year return: what $10,000 became

1 year
$10,000 $14,274
+42.74%
5 years
$10,000 $7,651
−23.49%
10 years
$10,000 $45,924
+359.24%

If you had invested $10,000 in Aurinia Pharmaceuticals Inc. (AUPH) 10 years ago, at the close on October 21, 2016, it would have been worth $45,924 at the close on October 21, 2026: +359.24% in total, +16.47% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+5.96%
2025+77.62%
2024−0.11%
2023+108.10%
2022−81.11%
2021+65.37%
2020−31.74%
2019+197.07%
2018+50.55%
2017+115.71%
2016 (partial year)−42.78%

As of October 21, 2026.

AUPH Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$283.06M$287.20M101.5%
2024$235.13M$5.75M2.4%
2023$175.51M−$78.02M−44.5%
2022$134.03M−$108.18M−80.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$283.06M$250.39M$106.56M$287.20M101.5%
2024$235.13M$206.89M$18.42M$5.75M2.4%
2023$175.51M$161.37M−$91.69M−$78.02M−44.5%
2022$134.03M$128.37M−$111.47M−$108.18M−80.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AUPH Valuation vs Biotechnology Median

Median of 608 stocks
MetricAUPHBiotechnology medianvs median
P/E7.4116.6055% below
P/S ratio7.2213.3046% below
Profit margin100.84%−38.31%139.1 pts above

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 9 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Aurinia Pharmaceuticals Inc. (AUPH) is capitalised at $2.25B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 128.

AUPH last closed at $16.90 on October 21, 2026. That is +$0.16 (+0.96%) against the previous close. Over the past 52 weeks the price has ranged from $11.48 to $19.25. The latest close sits 47.21% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $283.06M. Against the prior fiscal year total of $235.13M, that is a change of +20.38%. Net income for the same year was $287.20M. That is +4,893.08% against the prior fiscal year. Profit margin runs at 100.84%. That is 139.1 percentage points above the Biotechnology median of −38.31%. Trailing earnings per share are 2.28.

Across the 4 fiscal years on file, revenue moves from $134.03M in 2022 to $283.06M in 2025. Of those 4 years, 2 report positive net income.

Valuation Assessment

On trailing earnings, the shares are priced at 7.41 times earnings. That is 55.36% below the Biotechnology median of 16.6. On forward earnings the ratio is 15.97. The price-to-sales ratio is 7.22. On price-to-sales that is 45.72% below the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

The reported beta is 1.61. Daily returns over the trailing 10 years annualize to a volatility of 69.56%. The trailing one-year total return is +42.74%. Across 10 years the annualized return works out at +16.47%.

Growth & Income

No dividend is on file for AUPH.

The strongest complete calendar year on file is 2019 at +197.07%; the weakest is 2022 at −81.11%. Of the 9 complete calendar years on file, 6 finished higher. 2026 is still running; the total return is +5.96% year to date.

Peer Comparison

Aurinia Pharmaceuticals Inc. (AUPH) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Aurinia Pharmaceuticals Inc. AUPH $2.25B 7.4
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Aurinia Pharmaceuticals Inc. trades at a P/E of 7.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.

Visit website →